Zydus' Nesher Pharmaceuticals receives its first ANDA approval for Dextroamphetamine IR Tabs

From USFDA

Cadila Healthcare announced that Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA has received its first ANDA approval from USFDA to market Dextroamphetamine IR Tabs. The drug falls in the CNS segment and is the first product to be developed by the R&D team at Nesher.

Powered by Capital Market - Live News